Selective acidification and de-energization of A2780 ovarian cancer xenografts using lonidamine: A preliminary 1H and 31P MRS study
Kavindra Nath 1 , Ting Liu 1 , David S Nelson 1 , Daniel F Heitjan 1 , Dennis B Leeper 2 , Jerry D Glickson 1 , I-Wei Chen 1 , and Rong Zhou 1
University of Pennsylvania, Philadelphia,
Pennsylvania, United States,
Jefferson University, Philadelphia, Pennsylvania, United
In vivo 31P Magnetic Resonance Spectroscopy demonstrates
that A2780 ovarian cancer xenografts treated with the
monocarboxylate transporter-1 (MCT-1) inhibitor,
lonidamine (LND), exhibits a sustained and
tumor-selective decrease in delta pHi and pHe of 0.56
0.10 (p < 0.05) and 0.34 0.23 (p = 0.05) respectively.
Tumor bioenergetics (βNTP/Pi) decreased by 70.0 22% (p
< 0.05) and integrated intensities of the steady-state
tumor lactate were increased after 40 min. (p < 0.05)
relative to the baseline level following LND
administration. The decline of pHi and bioenergetics
could be critical parameters for chemo- and
thermo-sensitization of ovarian cancers.
This abstract and the presentation materials are available to members only;
a login is required.